Zeus Hygia and Patch House Labs join forces to take nutraceuticals beyond the pill

The agreement will see the two companies jointly develop and commercialise premium nutraceutical ingredients in advanced transdermal delivery formats

EU to withdraw Levamisole medicines over risk of rare, deadly brain disorder

The recommendation is based on new data from continuous safety monitoring of medicines in the EU

Will Forte joins Teva Pharmaceuticals to shine spotlight on Huntington’s disease

HD causes cognitive, behavioral, and physical challenges, including involuntary movements known as HD chorea, which can disrupt daily life

China nod to two Sanofi drugs for rare and complex conditions

Myqorzo, a selective small-molecule cardiac myosin inhibitor, is designed to improve functional capacity and relieve symptoms in oHCM

Mahajan Imaging & Labs launches AI-driven blood test to detect Alzheimer’s early

Over 8.8?million Indians aged 60 and above currently live with dementia,

GRIN Therapeutics launches global Phase 3 trial for groundbreaking GRIN-NDD therapy

GRIN-NDD is one of the most complex neurodevelopmental disorders with limited treatment options today

IRLAB launches Phase Ib Trial of IRL757 for Parkinson’s patients with Apathy

The multicenter study will enroll 75 patients across 16 sites in Germany, Bulgaria, Poland, and Spain

Denali clinches $275 million royalty deal to power potential breakthrough Hunter Syndrome therapy

Aelis Farma gets EMA nod for phase 2B trial of AEF0217 in down syndrome

AEF0217 is a first-in-class CB1 receptor signaling-specific inhibitor

Merck unveils first human data for Alzheimer’s candidates

The company also revealed that MK-2214 has received Fast Track Designation from the U.S. Food and Drug Administration